Archives
-
SCH772984 HCl: From ERK Inhibition to TERT
2026-10-01
SCH772984 HCl is a potent ERK1/2 inhibitor for dissecting MAPK signaling, adaptive resistance, and transcriptional control. This article connects direct ERK inhibition with TERT promoter chromatin, showing how to design assays that distinguish pathway blockade from secondary loss of stem-cell state or viability.
-
U0126: Practical MEK1/2 Inhibitor Workflows
2026-09-30
U0126 enables controlled MEK1/2 inhibition for linking ERK phosphorylation to proliferation, neuroinflammation, mitochondrial stress, and degradative pathways. This practical guide translates the reference study’s BV2 microglia workflow into assay-ready controls, dosing strategies, and troubleshooting decisions.
-
Doxycycline in Cancer Nanocarrier Assays
2026-09-30
Doxycycline is a tetracycline antibiotic with antimicrobial, antiproliferative, and metalloproteinase-inhibitory value in cancer research. This guide shows how to position it as a mechanistic comparator when evaluating targeted peptide nanocarriers, while preserving rigorous controls and interpretation.
-
U0126: From Mechanotransduction to Translational Insight
2026-09-29
A mechanistic guide to using U0126 as a MEK1/2 inhibitor for testing how matrix stiffness, focal adhesion signaling, ERK activity, and degradative pathways shape translational research decisions.
-
NEIL1, COL17A1, and Colorectal Cancer Initiation
2026-09-29
A Cell Reports study identifies NEIL1 as more than a base-excision-repair enzyme: it acts with SATB2, c-Myc, and RNA polymerase II to activate COL17A1 during colorectal cancer initiation. Genetic, mechanistic, immune, and intervention data connect this transcriptional pathway with tumor-promoting cytokines, reduced antitumor immunity, and potential sensitivity to combined NEIL1 and NF-κB inhibition.
-
Ang II–HIF-1α-HILPDA Axis in NPC Radioresistance
2026-09-28
The reference study identifies a local angiotensin II–AGT–HIF-1α–HILPDA circuit that suppresses ferroptosis and promotes radioresistance in nasopharyngeal carcinoma. Its combination of resistant-cell models, mechanistic assays, patient-tissue analysis, and xenograft experiments provides a framework for testing MAPK-linked radiosensitization while highlighting important limits on translation.
-
SMPD4, Ceramide, and Primary Cilia in Brain Development
2026-09-28
A 2024 study links SMPD4-dependent ceramide production to primary cilium maintenance, neural progenitor survival, and cerebellar development. By combining a mouse model with SMPD4-deficient human induced pluripotent stem cell-derived neural cells and ceramide rescue, the work offers a mechanistic framework for SMPD4-associated brain malformations while leaving important questions about lipid-specific mechanisms open.
-
PD98059: MEK Inhibitor Workflows for Cell Signaling
2026-09-27
Use PD98059 to test how MEK-dependent ERK1/2 signaling shapes cell-cycle progression, differentiation, and survival. In leukemia models, it is especially useful as an ERK1/2-pathway comparator alongside assays that distinguish these effects from ERK5 signaling.
-
SHC-1 Inhibition and CFTR Surface Abundance
2026-09-26
This study tests whether SHC-1-dependent CFTR internalization operates across airway and intestinal epithelial models, finding that the pathway is detectable in multiple cell lines but inhibitor-associated increases in surface CFTR are limited to CFBE cells. Because those increases coincided with changes in other membrane proteins, the results highlight cell-model dependence and the need to distinguish CFTR trafficking effects from broader changes in plasma membrane abundance.
-
AEBSF.HCl in Necroptosis: Read the Protease Class
2026-09-25
AEBSF.HCl is an irreversible serine protease inhibitor, but it is not a direct test of cathepsin B activity in necroptosis. This article connects its established research uses with lysosomal membrane permeabilization findings to clarify what the compound can—and cannot—tell you in cell-death assays.
-
Resazurin Sodium Salt in iPSC Drug Testing
2026-09-25
Use Resazurin sodium salt as a fast metabolic readout alongside—not instead of—CFTR function assays in cystic fibrosis iPSC models. This guide covers practical plate workflows, pilot conditions, and controls that help distinguish treatment-related toxicity from changes in cellular metabolism.
-
Psoralen-Induced Cholestasis via ERK1/2 Activation
2026-09-24
A 2024 zebrafish study links the estrogen-like effects of psoralen and isopsoralen to cholestatic liver injury and increased ERK1/2 phosphorylation. Its combination of estrogen-response markers, liver-function phenotyping, gene-expression analysis, and inhibitor-based rescue makes ERK1/2 a testable contributor to phytoestrogen-associated cholestasis, while leaving important questions about causality and human relevance open.
-
From CFTR Blockade to Trafficking Biology
2026-09-24
CFTR research benefits from separating channel activity from the number of channels at the epithelial surface. This article connects the rapid, reversible action of CFTRinh-172 with new findings on SHC-1-dependent CFTR trafficking—and offers a translational framework for designing experiments that distinguish these mechanisms.
-
SCH772984 HCl: ERK Inhibition Beyond Tumor Growth
2026-09-23
SCH772984 HCl is a potent ERK1/2 inhibitor for probing MAPK signaling and cancer biology. This article connects ERK perturbation to emerging evidence on TERT regulation, with a practical framework for distinguishing kinase engagement from epigenetic and cell-state effects.
-
Magneto-Piezoelectric Scaffolds for Infected Bone Repair
2026-09-23
Wu et al. developed a dual-responsive, 3D-printed scaffold that combines magnetic biofilm disruption with ultrasound-mediated metabolic activation of Icam1+ macrophages. The study links JAK2-STAT3-dependent oxidative phosphorylation to improved immune support for bone regeneration after infection control.